Hills Bank & Trust Co. Raises Stake in Celgene Co. (NASDAQ:CELG)

Hills Bank & Trust Co. increased its position in shares of Celgene Co. (NASDAQ:CELG) by 11.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,883 shares of the biopharmaceutical company’s stock after purchasing an additional 1,688 shares during the period. Hills Bank & Trust Co.’s holdings in Celgene were worth $1,498,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CELG. Macquarie Group Ltd. grew its position in shares of Celgene by 32.5% during the 3rd quarter. Macquarie Group Ltd. now owns 464,547 shares of the biopharmaceutical company’s stock worth $41,571,000 after buying an additional 114,074 shares in the last quarter. Koshinski Asset Management Inc. lifted its stake in shares of Celgene by 40.3% during the 3rd quarter. Koshinski Asset Management Inc. now owns 8,230 shares of the biopharmaceutical company’s stock worth $737,000 after purchasing an additional 2,366 shares during the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its stake in shares of Celgene by 5.8% during the 3rd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 18,100 shares of the biopharmaceutical company’s stock worth $1,620,000 after purchasing an additional 1,000 shares during the last quarter. Kentucky Retirement Systems purchased a new stake in shares of Celgene during the 3rd quarter worth $5,748,000. Finally, Neuberger Berman Group LLC lifted its stake in shares of Celgene by 2.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 408,133 shares of the biopharmaceutical company’s stock worth $36,524,000 after purchasing an additional 10,316 shares during the last quarter. 72.01% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:CELG traded up $0.04 during trading on Friday, hitting $95.51. The stock had a trading volume of 4,976,019 shares, compared to its average volume of 5,989,271. The stock has a market cap of $67.36 billion, a price-to-earnings ratio of 12.55, a PEG ratio of 0.44 and a beta of 1.68. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $97.07. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 2.42.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.45 by $0.10. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.01 billion. Celgene had a return on equity of 106.69% and a net margin of 30.10%. Celgene’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $2.05 earnings per share. As a group, equities analysts anticipate that Celgene Co. will post 9.85 EPS for the current fiscal year.

In other Celgene news, Director Ernest Mario acquired 2,000 shares of the company’s stock in a transaction on Tuesday, February 12th. The shares were bought at an average cost of $89.99 per share, with a total value of $179,980.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.39% of the stock is currently owned by company insiders.

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Celgene from a “buy” rating to a “hold” rating in a research note on Wednesday, April 3rd. ValuEngine upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. Mizuho set a $103.00 price target on Celgene and gave the company a “buy” rating in a research note on Friday, April 5th. Barclays cut Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target for the company. in a research note on Friday, May 3rd. Finally, BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $95.96.

ILLEGAL ACTIVITY NOTICE: This article was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/11/hills-bank-trust-co-purchases-1688-shares-of-celgene-co-celg.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: What are the advantages of the Stochastic Momentum Index?

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.